Treatment of arterial hypertension with ramipril. Results of the Austrian Ramipril Trial (ART I) - An open multicentre general practice study

Clinical Drug Investigation

Volumn 12, Issue 1, 1996, Pages 8-15

  Brandt, Dieter ^a,b  

^a Rehab Ctr Heart Circulatory C   (Austria)

^b Rehabilitationszentrum F Herz K   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; RAMIPRIL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO; XEROSTOMIA;

EID: 0029738554     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199612010-00002     Document Type: Article

References (37)

1. McMahon FG. Blood pressure and the risks of cardiovascular disease. In: Swales textbook of hypertension. Oxford, UK: Blackwell Scientific Publications, 1994
2. Grobecker H-F. Hemmstoffe des Konversionsenzyms. Pharmakologie und klinische Pharmakologie. Basic: Aesopus Verlag, 1991: 104
3. Kostis JB. Angiotensin converting enzyme inhibitors. II. Clinical use. Am Heart J 1988; 116: 1591-605
4. Cushman DW, Wang FL, Fung WC, et al. Comparisons in vitro, ex vivo and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989; 28 Suppl. 2: S115-S31
5. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989; 7 Suppl. 5: 11-6
6. Unger T. Pharmakologisches Profil und antihypertensiver Wirkungsmechanismus der Konversionsenzyminhibitoren [in German]. Nieren Hochdruckkr 1989; 55-60
7. Crozier IG, Ikram H, Nicholls MG, et al. Global and regional hemodynamic effects of ramipril in congestive heart failure. J Cardiovasc Pharmacol 1989; 14: 688-93
8. Dzau VJ. The tissue renin-angiotensin-system: implications for angiotensin converting enzyme inhibition. Curr Opin Cardiol 1988; 3 Suppl. 1: 97-102
9. Johnston CI, Cubela R, Sakaguchi K, et al. Mode of action of ACE inhibitors: plasma and tissue inhibition. In: Rand MJ, Raper C, editors. Pharmacology. Amsterdam: Elsevier, 1987: 537-43
10. Johnston CI, Kolizuki M. Angiotensin converting enzyme localization, regulation and inhibition. In: MacGregor GA, Sever PS, editors. Current advances in ACE inhibition. Edinburgh: Churchill Livingstone, 1989: 3-7
11. Dzau VJ. Circulating versus local renin angiotensin system in cardiovascular homeostasis. Circulation 1988; 77 Suppl. 1: 14-113
12. Manhem PJO, Ball SG, Mortan JJ, et al. A dose-response study of HOE 498, a new nonsulphydryl converting enzyme inhibitor, on blood pressure, pulse rale and the renin-angiotensin-aldosterone system in normal man. Br J Clin Pharmacol 1985; 20: 27-35
13. Unger T, Ganten D, Lang RE. Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J Cardiovasc Pharmacol 1986; 8 Suppl. 10: 75-81
14. Klein W, Farr Ch, Steyer GE. Therapeutischer Nutzen des lipophilen ACE-Hemmers bei Herz-Kreislauferkrankungen [in German]. Arzneimittelpraxis 1991; 21: 911-7
15. Unger T, Ganten D, Lang RE. Effects of converting enzyme inhibitors on tissue converting enzyme and angiotensin II: therapeutic implications. Am J Cardiol 1987; 59: 18D-22D
16. Vasmant D, Bender N. The renin angiotensin system and ramipril, a new converting enzyme inhibitor. J Cardiovasc Pharmacol 1989; 14 Suppl. 4: 46-52
17. Todd PA, Benfield P. Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990; 39: 110-35
18. Moursi MG, Ganten D, Lang RE, et al. Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril, and perindopril, in stroke-prone spontaneously hypertensive rats. J Hypertens 1986; 4 Suppl. 3: 495-8
19. Witte PU, Irmisch R, Hajdù P, et al. Phurmacokinetics and pharmacodynamics of a novel orally active angiotensin convening enzyme inhibitor (HOE 498) in healthy subjects. Eur J Clin Pharmacol 1984; 27: 577-81
20. Karlberg BE, Lindström T, Rosenqvist U, et al. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension. Am J Cardiol 1987; 59: 104D-109D
21. Bauer B, Lorenz H, Zahlten R, et al. An open multicenter study to assess the long-term efficacy, tolerance and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1989; 13 Suppl. 3: 570-4
22. Koenig W on behalf or the Multicentre Study Group. Ramipril vs lisinopril in the treatment of mild to moderate primary hypertension - a randomised double-blind multicentre trial. Drug Invest 1992; 4: 450-7
23. Spiecker C, Zidek W, Vetter H, et al. Ambulatory 24h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril. J Int Med Res 1991; 19: 394
24. Witte PU, Walter U. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension. Am J Cardiol 1987; 59: 115D-120D
25. Zabludowski J, Rosenfeld J, Akbary MA, et al. A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension. Curr Med Res Opin 1988; 11: 93-106
26. Eichstädt HW, Felix R, Langer M. Use of nuclear magnetic-resonance imaging to show regression of hypertrophy with ramipril treatment. Am J Cardiol 1987; 59: 98D-103D
27. Götz R, Drechsler U, Heidbreder E, et al. Einfluss des Angiotensin-Konversionsenzym-Inhibitors Ramipril auf Proteinurie, Blutdruck und Nierenfunktion bei histologisch gesicherten Glomerulonephritiden mit nephrotischem Syndrom [in German]. Z Kardiol 1988; 77 Suppl. 3: 65-8
28. Hailab M, Billiard A, Lejeune JJ, et al. Dissociation des effets hypotenseurs et hémodynamiques renaux d'un inhibiteur de l'enzyme de con version (EC) chez des DIDs avec nephropatie debuntante [in French] [abstract 19]. Diabetes Metab Rev 1989; 15: 6
29. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically presents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A 1989; 11: 1325-50
30. Ocon-Pujadas J, Debusmann ER, Jane F, et al. Pharmacodynamic effects of a single 10mg dose of the angiotensin-converting enzyme inhibitor ramipril in patients with impaired renal function. J Cardiovasc Pharmacol 1989; 13 Suppl. 3: 45-8
31. Janka HK, Nuber A, Mehnert H. Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin dependent diabetes mellitus. Arzneimittel Forschung 1990; 40: 432-75
32. Predel HG, Düsing R, Bäcker A, et al. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. Am J Cardiol 1987; 59: 143D-148D
33. Reinisch W, Hoffman H, Hoffman W. Hypertoniebehandlung mit dem neuen ACE-Hemmer Ramipril. Ergebnisse einer prospektiven klinischen Untersuchung an 2354 Patienten [in German]. Ther Öster 1992; 7 (2): 112-9
34. Bortz WM. Review of ACE inhibitor usage in elderly hypertensives. International Symposium: normal aging and clinical problems in the elderly. Montreux, 1987
35. Brunner HR, Nussberger J, Weber B. Effects of angiotensin converting enzyme inhibition: a clinical point of view. J Cardiovasc Pharmacol 1985; 7 Suppl. 4: 573-81
36. Moiseyev VS, Ivleva AJ, Antija ID, et al. Cardiovascular and renal effects of ramipril. Lancet 1989; I: 846
37. Marre M, Hallab M, Billiard A, et al. Dissociated effects of an angiotensin converting enzyme inhibitor on systemic blood pressure and renal haemodynamics in incipient diabetic nephropathy. Diabetologia 1989; 32: 514A